Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 Jul:171:73-7.
doi: 10.1192/bjp.171.1.73.

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study

I Pelc  1 , P Verbanck, O Le Bon, M Gavrilovic, K Lion, P Lehert
Affiliations
Clinical Trial

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study

I Pelc et al. Br J Psychiatry. 1997 Jul.

Abstract

Background: Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.

Method: In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).

Results: For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.

Conclusion: This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.

PubMed Disclaimer

Publication types

MeSH terms